JP4668346B2 - Ｎ−（２−ヒドロキシエチル）−ｎ−メチル−４−（キノリン−８−イル（１−（チアゾール−４−イルメチル）ピペリジン−４−イリデン）メチル）ベンズアミド、その製造方法、並びに疼痛、不安及びうつ病の治療のためのその使用 - Google Patents

Ｎ−（２−ヒドロキシエチル）−ｎ−メチル−４−（キノリン−８−イル（１−（チアゾール−４−イルメチル）ピペリジン−４−イリデン）メチル）ベンズアミド、その製造方法、並びに疼痛、不安及びうつ病の治療のためのその使用 Download PDF

Info

Publication number
JP4668346B2
JP4668346B2 JP2009533278A JP2009533278A JP4668346B2 JP 4668346 B2 JP4668346 B2 JP 4668346B2 JP 2009533278 A JP2009533278 A JP 2009533278A JP 2009533278 A JP2009533278 A JP 2009533278A JP 4668346 B2 JP4668346 B2 JP 4668346B2
Authority
JP
Japan
Prior art keywords
methyl
quinolin
ylidene
piperidin
benzamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009533278A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010506910A (ja
JP2010506910A5 (enExample
Inventor
カーン・ブイ
カシー・ダンツマン
グレン・アーンスト
ヴァレリー・ヘーシュ
トマス・ハジック
メガン・マーフィ・キング
ジエ・リウー
ジンボー・ヤン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2010506910A publication Critical patent/JP2010506910A/ja
Publication of JP2010506910A5 publication Critical patent/JP2010506910A5/ja
Application granted granted Critical
Publication of JP4668346B2 publication Critical patent/JP4668346B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
JP2009533278A 2006-10-20 2007-10-19 Ｎ−（２−ヒドロキシエチル）−ｎ−メチル−４−（キノリン−８−イル（１−（チアゾール−４−イルメチル）ピペリジン−４−イリデン）メチル）ベンズアミド、その製造方法、並びに疼痛、不安及びうつ病の治療のためのその使用 Expired - Fee Related JP4668346B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86232706P 2006-10-20 2006-10-20
PCT/SE2007/000924 WO2008048171A1 (en) 2006-10-20 2007-10-19 N- (2 -hydroxyethyl) -n-methyl- 4- (quinolin- 8-yl (1- (thiazol-4- ylmethyl) piperidin- 4 -ylidene) methyl) benzamide, the process of making it as well as its use for the treatment of pain, anxiety and depression.

Publications (3)

Publication Number Publication Date
JP2010506910A JP2010506910A (ja) 2010-03-04
JP2010506910A5 JP2010506910A5 (enExample) 2010-07-15
JP4668346B2 true JP4668346B2 (ja) 2011-04-13

Family

ID=39314285

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009533278A Expired - Fee Related JP4668346B2 (ja) 2006-10-20 2007-10-19 Ｎ−（２−ヒドロキシエチル）−ｎ−メチル−４−（キノリン−８−イル（１−（チアゾール−４−イルメチル）ピペリジン−４−イリデン）メチル）ベンズアミド、その製造方法、並びに疼痛、不安及びうつ病の治療のためのその使用

Country Status (32)

Country Link
US (2) US7659286B2 (enExample)
EP (1) EP2079735B1 (enExample)
JP (1) JP4668346B2 (enExample)
KR (1) KR20090065534A (enExample)
CN (1) CN101528739B (enExample)
AR (1) AR063345A1 (enExample)
AT (1) ATE543818T1 (enExample)
AU (2) AU2007313515B2 (enExample)
BR (1) BRPI0717631A2 (enExample)
CA (1) CA2667041C (enExample)
CL (1) CL2007003009A1 (enExample)
CO (1) CO6180450A2 (enExample)
CY (1) CY1112718T1 (enExample)
DK (1) DK2079735T3 (enExample)
ES (1) ES2379519T3 (enExample)
HR (1) HRP20120344T1 (enExample)
IL (1) IL197876A0 (enExample)
MX (1) MX2009003974A (enExample)
MY (1) MY148880A (enExample)
NO (1) NO20091969L (enExample)
NZ (1) NZ577060A (enExample)
PE (2) PE20080892A1 (enExample)
PL (1) PL2079735T3 (enExample)
PT (1) PT2079735E (enExample)
RS (1) RS52260B (enExample)
RU (1) RU2454414C2 (enExample)
SA (1) SA07280549B1 (enExample)
SI (1) SI2079735T1 (enExample)
TW (1) TW200826939A (enExample)
UA (1) UA97648C2 (enExample)
UY (1) UY30652A1 (enExample)
WO (1) WO2008048171A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1641757A1 (en) * 2003-05-16 2006-04-05 AstraZeneca AB Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
MY148880A (en) 2006-10-20 2013-06-14 Astrazeneca Ab N-(2-hydroxyethyl)-n-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide, the process of making it as well as its use for the treatment of pain, anxiety and depression
BRPI0912756A2 (pt) * 2008-05-20 2015-10-13 Astrazeneca Ab método para tratar transtorno depressivo maior ansioso em um animal de sangue quente, uso de um composto, composto, e, composição farmacêutica
CN101906078B (zh) * 2009-06-08 2012-02-01 上海威智医药科技有限公司 噻唑衍生物的合成方法
CN102106807B (zh) * 2009-12-29 2013-03-27 上海中西制药有限公司 一种固体制剂的制备方法及所得固体制剂
WO2016099393A1 (en) * 2014-12-19 2016-06-23 Pharmnovo Ab Diarylmethylidene piperidine derivatives and their use as delta opioid receptor agonists
EP3853435B1 (en) 2018-09-21 2024-08-21 Garland Industries, Inc. Helical hardbanding

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2898339A (en) * 1957-07-29 1959-08-04 Wm S Merrell Co N-substituted benzhydrol, benzhydryl, and benzhydrylidene piperidine
US4581171A (en) * 1983-07-27 1986-04-08 Janssen Pharmaceutica, N.V. [[Bis(aryl)methylene]-1-piperidinyl]alkyl-pyrimidinones useful for treating psychotropic disorders
TW548271B (en) * 1996-12-20 2003-08-21 Astra Pharma Inc Novel piperidine derivatives having an exocyclic double bond with analgesic effects
AU2009799A (en) * 1997-12-24 1999-07-19 Ortho-Mcneil Pharmaceutical, Inc. 4-(aryl(piperidin-4-yl)) aminobenzamides which bind to the delta-opioid receptor
US6492375B2 (en) * 1998-06-30 2002-12-10 Neuromed Technologies, Inc. Partially saturated calcium channel blockers
SE9904673D0 (sv) * 1999-12-20 1999-12-20 Astra Pharma Inc Novel compounds
AU784848B2 (en) 1999-12-20 2006-07-06 Zalicus Pharmaceuticals Ltd. Partially saturated calcium channel blockers
CN1426411A (zh) * 2000-03-03 2003-06-25 奥索-麦克尼尔药品公司 3－(二芳基亚甲基)－8－氮杂双环[3.2.1]辛烷衍生物
SE0001208D0 (sv) * 2000-04-04 2000-04-04 Astrazeneca Canada Inc Novel compounds
SE0101768D0 (sv) * 2001-05-18 2001-05-18 Astrazeneca Ab Novel compounds
US20040204404A1 (en) * 2002-09-30 2004-10-14 Robert Zelle Human N-type calcium channel blockers
SE0300105D0 (sv) * 2003-01-16 2003-01-16 Astrazeneca Ab Diarylmethylidene piperdine derivatives, preparations thereof and uses thereof
SE0301444D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
SE0301442D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations therof and uses thereof
EP1641757A1 (en) * 2003-05-16 2006-04-05 AstraZeneca AB Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
SE0301445D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
SE0301441D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
SE0400025D0 (sv) * 2004-01-09 2004-01-09 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
WO2005087742A1 (en) 2004-03-08 2005-09-22 Exelixis, Inc. Metabolic kinase modulators and methods of use as pesticides
MY148880A (en) * 2006-10-20 2013-06-14 Astrazeneca Ab N-(2-hydroxyethyl)-n-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide, the process of making it as well as its use for the treatment of pain, anxiety and depression

Also Published As

Publication number Publication date
CY1112718T1 (el) 2016-02-10
TW200826939A (en) 2008-07-01
EP2079735A4 (en) 2010-12-29
EP2079735A1 (en) 2009-07-22
CL2007003009A1 (es) 2008-06-06
ES2379519T3 (es) 2012-04-26
EP2079735B1 (en) 2012-02-01
RU2009111337A (ru) 2010-11-27
HK1131556A1 (en) 2010-01-29
IL197876A0 (en) 2009-12-24
KR20090065534A (ko) 2009-06-22
CA2667041C (en) 2011-09-06
ATE543818T1 (de) 2012-02-15
CA2667041A1 (en) 2008-04-24
RU2454414C2 (ru) 2012-06-27
AR063345A1 (es) 2009-01-21
SA07280549B1 (ar) 2010-09-29
AU2007313515A1 (en) 2008-04-24
PL2079735T3 (pl) 2012-07-31
CN101528739B (zh) 2011-11-30
MX2009003974A (es) 2009-04-27
RS52260B (sr) 2012-10-31
PE20140634A1 (es) 2014-06-19
JP2010506910A (ja) 2010-03-04
PT2079735E (pt) 2012-05-07
UY30652A1 (es) 2008-05-31
US20080182875A1 (en) 2008-07-31
MY148880A (en) 2013-06-14
US20100160374A1 (en) 2010-06-24
BRPI0717631A2 (pt) 2013-10-29
WO2008048171A1 (en) 2008-04-24
SI2079735T1 (sl) 2012-05-31
CO6180450A2 (es) 2010-07-19
UA97648C2 (ru) 2012-03-12
NZ577060A (en) 2011-01-28
US7659286B2 (en) 2010-02-09
HRP20120344T1 (hr) 2012-05-31
NO20091969L (no) 2009-05-20
AU2010226996A1 (en) 2010-10-28
DK2079735T3 (da) 2012-05-21
PE20080892A1 (es) 2008-09-11
US7977355B2 (en) 2011-07-12
AU2007313515B2 (en) 2010-11-25
CN101528739A (zh) 2009-09-09

Similar Documents

Publication Publication Date Title
JP4668346B2 (ja) Ｎ−（２−ヒドロキシエチル）−ｎ−メチル−４−（キノリン−８−イル（１−（チアゾール−４−イルメチル）ピペリジン−４−イリデン）メチル）ベンズアミド、その製造方法、並びに疼痛、不安及びうつ病の治療のためのその使用
TWI477499B (zh) 代謝型麩胺酸受體異唑配位體及其作為增效劑之用途－２８６
CN1185228C (zh) 治疗疼痛的羟苯基－亚哌啶－4－基－甲基－苯甲酰胺衍生物
SK82298A3 (en) Novel compounds with analgesic effect
EP1789410B1 (en) Methylene dipiperidine derivatives
CN1993338B (zh) 二芳基甲基哌嗪衍生物及其制备方法和用途
US10160745B2 (en) Piperidine and azepine derivatives as prokineticin receptor modulators
JP2007521286A (ja) 肥満治療用のｍｃｈアンタゴニスト
JP2005508290A (ja) ４−（フェニル−（ピペリジン−４−イル）−アミノ）−ベンズアミド誘導体及び疼痛、不安症又は胃腸障害の治療のためのその使用
JP2005508289A (ja) ４−（フェニル−（ピペリジン−４−イル）−アミノ）−ベンズアミド誘導体及び疼痛、不安症又は胃腸障害の治療のためのその使用
HK1131556B (en) N- (2 -hydroxyethyl) -n-methyl- 4- (quinolin- 8-yl (1- (thiazol-4- ylmethyl) piperidin- 4 -ylidene) methyl) benzamide, the process of making it as well as its use for the treatment of pain, anxiety and depression
CN101128447A (zh) 二芳基甲基哌嗪衍生物，其制备及其用途
EP3010900B1 (en) 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors
JP2011512407A (ja) 化合物（Ｒ）−Ｎ＊６＊−エチル−６，７−ジヒドロ−５Ｈ−インデノ（５，６−ｄ）チアゾール−２，６−ジアミン及びその抗精神病薬としての使用
UA77672C2 (en) 4-(phenyl-piperazinyl-methyl)-benzamide derivatives and use thereof for the treatment of pain, anxiety or gastrointestinal disorders, a process for preparation thereof and a pharmaceutical composition based thereon

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100525

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100525

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20100525

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20100625

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100810

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20101221

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110112

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140121

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees